From Deseret News archives:
Osteoporosis drug also reduces breast cancer
Preliminary data from the multi-center "STAR Study" (the "Study of Tamoxifen and Raloxifene"), which included 83 Utah women who took part through the Huntsman Cancer Institute, was released Monday by the National Cancer Institute and the National Surgical Adjuvant Breast and Bowel Project, a network of cancer researchers.
The study found both drugs cut the risk of developing invasive breast cancer in half. But researchers found women who took raloxifene had 36 percent fewer uterine cancers (a very rare but serious side effect of tamoxifen) and 29 perfect fewer blood clots than those taking tamoxifen. Both drugs increase a woman's risk of blood clots compared to those who take neither drug.
"It's clear that we feel raloxifene has been the winner of this trial," Dr. D. Lawrence Wickerham, NSABP associate chairman and STAR protocol officer, said during a teleconference with reporters Monday afternoon.
"We think this gives women a real choice when addressing two of the leading causes of mortality and morbidity as they age breast cancer and hip fracture," said Dr. Leslie Ford, associate director of clinical research at the NCI.
This year, about 212,000 women, most of them past menopause, will be diagnosed with breast cancer. More than 40,000 will die of the disease. For the study, women were randomly assigned to receive one or the other of the two medicines, with a placebo version of the other to be sure that neither doctor nor patient could tell who was getting which drug.
Tamoxifen is marketed as Nolvadex, raloxifene as Evista. Tamoxifen has been used for 30 years to treat breast cancer patients. In 1998 it was approved as a prevention tool in high-risk, pre- and postmenopausal women. Raloxifene, also taken by pill, got FDA approval in 1997 to prevent osteoporosis in postmenopausal women but is not approved for use by women before menopause.
Comments
- Va. Tech staff warned families first 9:37 p.m.
- Senate preserves care program 9:37 p.m.
- Gitmo ex-prosecutor loses new job 9:36 p.m.
- Now's a good time for flu shot 9:34 p.m.
- November very dry, very mild 9:33 p.m.
- Texas' final obstacle to BCS title game 9:31 p.m.
- Y. profs: Beck not all-knowing 9:29 p.m.
- DTV tops list of online coupons 9:24 p.m.
- UVEF Awards event is Thursday 9:23 p.m.
- Regulators shut down Ohio bank 9:22 p.m.
- Mr. Football 2009: Tuni Kanuch
- Ed Smart infuriated with revelations
- 5A high school football All-State
- Miller predicted Tiger's rough road
- Utah Jazz going green with unis
- 4A high school football: All-State
- Harpring's NBA career is over
- Nutty Putty Cave to be sealed today
- MVPs wrap up stellar prep careers
- Jazz: Miles, Kirilenko to play Friday
- Hall reprimanded by MWC
409 - Why is Y. ignoring spew of hatred?
293 - BYU says Hall incident resolved
247 - Letters: Liberal because LDS
236 - 2 citations issued at Y.-U. game
189 - Hate not limited to 1 in-state rivalry
184 - Aggies shoot past Cougars
179 - Religion in politics is tiresome
158 - N.Y. Senate rejects gay marriage
117 - Max Hall: a fixture in rivalry lore
117
Trolley Square's annual Holiday Open House will feature visits with...
That does it — I'm having an affair! Thanks to Tiger Woods, David...
First, a big thank you to all who posted questions here for me to ask...
This is an extremely well-written article. I was really happy it was George...
Love em. Love em. Love em. I have a green Hornacek (thank you ebay) and I...
Where is Rio Tinto Stadium?
Congrats to Merlin. I'm too young to have ever seen him play in person, but...
To the point, read the writings of John Locke (Second Treatise of Civil...
so sorry about the loss.. Can I send flowers? or perhaps a thank you card for...
maybe Kyle can recruit some better sports
Maybe it was an individual problem, or should everyone be forced to learn....
No wonder why he sleeps alone..gross
Hey Michigan---Last time I checked, all of the (global warming) fear and...



You can be the first to comment on this story.